Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
26 Feb 2019
Historique:
received: 19 11 2018
accepted: 20 02 2019
entrez: 28 2 2019
pubmed: 28 2 2019
medline: 27 6 2019
Statut: epublish

Résumé

Insulinoma represents hypoglycemia as a predominant symptom; the autonomic symptoms may be resolved by chronically recurrent hypoglycemia resulting in the persistence of non-specific symptoms alone. Therefore, it has been estimated that there are many patients in whom the disease takes longer to diagnose and has remained undiagnosed. Although some parameters exist for the definitive diagnosis of the disease, there are currently no indices for early screening. Indices of glycemic control, hemoglobin A1c (HbA1c), and glycated albumin (GA) may be useful for the screening of patients with insulinoma having chronic hypoglycemia because the values become low in such a condition. Because there are no articles that have reported the point, we examine the effective cutoff values of HbA1c and GA for the diagnosis of insulinoma in the present study. In a multicenter cross-sectional study, 31 patients with insulinoma were included for comparison with 120 control subjects with normal glucose tolerance based on 75 g oral glucose tolerance tests whose characteristics were matched to the patients. The primary outcomes were optimal cutoff values of HbA1c and GA for the screening of insulinoma. HbA1c was significantly lower in the insulinoma group at 4.7 ± 0.4% compared to the healthy control group at 5.7 ± 0.3% (p < 0.001), and GA was significantly lower in the insulinoma group at 11.6 ± 1.8% compared to the healthy control group at 14.5 ± 1.0% (p < 0.001). According to a receiver operating characteristic (ROC) analysis, optimal cutoff values of HbA1c and GA for the diagnosis of insulinoma were 5.0 and 12.4%, respectively. Area under the curve values of HbA1c and GA were 0.970 and 0.929, respectively, showing no significant difference (p = 0.399). In the present study, HbA1c and GA values in patients with insulinoma were significantly lower compared to the healthy controls, and effective cutoff values for screening were shown in the diagnosis of insulinoma for the first time. HbA1c and GA can be useful indices for insulinoma screening. Because malignant insulinoma have a similar diagnostic process to that of benign insulinoma, these could be useful for malignant insulinoma.

Sections du résumé

BACKGROUND BACKGROUND
Insulinoma represents hypoglycemia as a predominant symptom; the autonomic symptoms may be resolved by chronically recurrent hypoglycemia resulting in the persistence of non-specific symptoms alone. Therefore, it has been estimated that there are many patients in whom the disease takes longer to diagnose and has remained undiagnosed. Although some parameters exist for the definitive diagnosis of the disease, there are currently no indices for early screening. Indices of glycemic control, hemoglobin A1c (HbA1c), and glycated albumin (GA) may be useful for the screening of patients with insulinoma having chronic hypoglycemia because the values become low in such a condition. Because there are no articles that have reported the point, we examine the effective cutoff values of HbA1c and GA for the diagnosis of insulinoma in the present study.
METHODS METHODS
In a multicenter cross-sectional study, 31 patients with insulinoma were included for comparison with 120 control subjects with normal glucose tolerance based on 75 g oral glucose tolerance tests whose characteristics were matched to the patients. The primary outcomes were optimal cutoff values of HbA1c and GA for the screening of insulinoma.
RESULTS RESULTS
HbA1c was significantly lower in the insulinoma group at 4.7 ± 0.4% compared to the healthy control group at 5.7 ± 0.3% (p < 0.001), and GA was significantly lower in the insulinoma group at 11.6 ± 1.8% compared to the healthy control group at 14.5 ± 1.0% (p < 0.001). According to a receiver operating characteristic (ROC) analysis, optimal cutoff values of HbA1c and GA for the diagnosis of insulinoma were 5.0 and 12.4%, respectively. Area under the curve values of HbA1c and GA were 0.970 and 0.929, respectively, showing no significant difference (p = 0.399).
CONCLUSIONS CONCLUSIONS
In the present study, HbA1c and GA values in patients with insulinoma were significantly lower compared to the healthy controls, and effective cutoff values for screening were shown in the diagnosis of insulinoma for the first time. HbA1c and GA can be useful indices for insulinoma screening. Because malignant insulinoma have a similar diagnostic process to that of benign insulinoma, these could be useful for malignant insulinoma.

Identifiants

pubmed: 30808334
doi: 10.1186/s12885-019-5389-7
pii: 10.1186/s12885-019-5389-7
pmc: PMC6390316
doi:

Substances chimiques

Glycated Hemoglobin A 0
Glycation End Products, Advanced 0
Serum Albumin 0
hemoglobin A1c protein, human 0
Glycated Serum Albumin 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

174

Références

J Clin Endocrinol Metab. 2000 Sep;85(9):3222-6
pubmed: 10999812
Clin Chim Acta. 2002 Oct;324(1-2):61-71
pubmed: 12204426
Mayo Clin Proc. 1991 Jul;66(7):711-9
pubmed: 1677058
Clin Chim Acta. 2007 Mar;378(1-2):48-52
pubmed: 17141207
Endocr Rev. 1991 Nov;12(4):356-71
pubmed: 1760993
Mayo Clin Proc. 1976 Jul;51(7):417-29
pubmed: 180358
Ann Surg. 2008 Jan;247(1):165-72
pubmed: 18156937
Endocr Relat Cancer. 2008 Jun;15(2):409-27
pubmed: 18508996
J Clin Endocrinol Metab. 2009 Apr;94(4):1069-73
pubmed: 19141587
Nat Rev Endocrinol. 2009 Nov;5(11):628-31
pubmed: 19844250
Dig Dis Sci. 1991 Jul;36(7):933-42
pubmed: 2070707
Neuroendocrinology. 2012;95(2):98-119
pubmed: 22261919
Eur J Endocrinol. 2014 Mar 14;170(4):R147-57
pubmed: 24459236
J Diabetes Investig. 2012 Feb 20;3(1):39-40
pubmed: 24843544
BMC Endocr Disord. 2018 Dec 6;18(1):92
pubmed: 30522468
Virchows Arch A Pathol Anat Histol. 1975;365(4):275-88
pubmed: 46649
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693

Auteurs

Keiichi Torimoto (K)

First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan. torimoto@med.uoeh-u.ac.jp.

Yosuke Okada (Y)

First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan.

Yoshiya Tanaka (Y)

First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan.

Atsuko Matsuoka (A)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, 650-0017, Japan.

Yushi Hirota (Y)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, 650-0017, Japan.

Wataru Ogawa (W)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, 650-0017, Japan.

Yoshifumi Saisho (Y)

Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.

Isao Kurihara (I)

Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.

Hiroshi Itoh (H)

Department of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.

Shinya Inada (S)

Department of Internal Medicine, Kawanishi City Hospital, Hyogo, 666-0195, Japan.

Masafumi Koga (M)

Department of Internal Medicine, Hakuhokai Central Hospital, Hyogo, 669-0953, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH